How can we use anthracylines in the management of newly diagnosed metastatic breast cancer patients overexpressing HER-2?
Ann Oncol
.
2008 Jun;19(6):1203.
doi: 10.1093/annonc/mdn152.
Epub 2008 Mar 28.
Authors
H Harputluoglu
,
K Altundag
PMID:
18375523
DOI:
10.1093/annonc/mdn152
No abstract available
Publication types
Letter
MeSH terms
Anthracyclines / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism
Breast Neoplasms / secondary
Female
Humans
Receptor, ErbB-2 / biosynthesis*
Substances
Anthracyclines
Receptor, ErbB-2